Full text
Earnings transcript
Read the complete earnings call transcript.
PGEN
Precigen, Inc.
$6.39
-0.81
(-11.26%)
| Exchange: | NASDAQ |
| Market Cap: | 2.286B |
| Shares Outstanding: | 167.066M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | BiotechnologyView industry performance | |||||
| CEO: | Helen Sabzevari | |||||
| Full Time Employees: | 160 | |||||
| Address: |
| |||||
| Website: | https://www.precigen.com |
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression’s timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Click to read more…
Revenue Segmentation
Industry Peers
| TICKER | COMPANY | MKT CAP | P/E | FWD P/E | ROIC |
|---|---|---|---|---|---|
| PGEN | Precigen, Inc. | 2.3B | — | 37.6 | -27.8% |
 NAMS | NewAmsterdam Pharma Company N.V. | 2.3B | — | — | -38.7% |
 HRMY | Harmony Biosciences Holdings, Inc. | 2.2B | 12.9 | 9.6 | 15.0% |
 ETNB | 89bio, Inc. | 2.2B | — | — | -82.7% |
 AUPH | Aurinia Pharmaceuticals Inc. | 2.2B | 7.1 | 17.6 | 21.3% |
 MBX | MBX Biosciences, Inc. Common Stock | 2.4B | — | — | -28.6% |
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 6,225 | 3,925 | 9,684 |
| Gross Profit | 106 | -342 | 3,588 |
| EBITDA | -89,226 | -123,496 | -243,573 |
| Operating Income | -99,758 | -135,029 | -106,600 |
| Net Income | -95,904 | -126,235 | -250,642 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 151,043 | 145,266 | 155,505 |
| Total Liabilities | 32,545 | 106,753 | 134,594 |
| Total Stockholders Equity | 118,498 | 66,730.999 | 20,911 |
| Total Debt | 7,097 | 5,502 | 98,290 |
| Cash and Cash Equivalents | 7,578 | 29,517 | 30,234 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -66,930 | -68,173 | -87,831 |
| Capital Expenditure | -1,536 | -8,584 | 0 |
| Free Cash Flow | -68,466 | -76,757 | -87,831 |
| Net Income | -95,904 | -126,235 | -250,642 |
| Net Change in Cash | -40,748 | 21,669 | 0 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 738,546.828 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 1,345,952.813 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 982,287.500 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 602,265.470 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 1,082,603.169 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 795,015.271 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 308,592.667 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 674,784.221 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 455,537.929 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 3,846,134.378 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 7,009,325.867 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 5,115,464.017 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 1.500 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 2.210 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 1.010 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 2 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates PGEN intrinsic value between $13.88 – $21.57 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about PGEN valuation
Is Precigen, Inc. (PGEN) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Precigen, Inc. (PGEN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is PGEN a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PGEN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is PGEN’s P/E ratio?
You can see PGEN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for PGEN?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is PGEN a good long-term investment?
Whether PGEN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
PGEN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-11.26
Trading Metrics:
| Open: | 7.2 | Previous Close: | 7.2 | |
| Day Low: | 6.31 | Day High: | 7.2 | |
| Year Low: | 3.04 | Year High: | 8.98 | |
| Price Avg 50: | 7.31 | Price Avg 200: | 5.16 | |
| Volume: | 5.472M | Average Volume: | 5.085M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
